Mary McCreary is one of many ALS patients who are being denied coverage for Radicava – a new drug proven to slow the progression of the fatal, degenerative disease by up to 30%. Her insurance carrier refuses to provide access to this drug.
Mary was devastated when she learned of her ALS diagnosis in 2014. Still, she’s successfully managed her disease and is considered a “slow progressor.” ALS progression is usually different for every patient and many believe that disease duration should not be a factor in insurance coverage determination.
In fact, Medicare and other insurers are providing access to Radicava, sometimes without any additional conditions – yet Aetna is denying coverage to scores of patients. Mary believes this is unconscionable, as this drug gives patients like her a chance to survive as they wait for more treatment options to be found.
In recent months, supporters like you have stood with other ALS patients across the country – helping them win vital access to this new drug. Your voices have already helped encourage other insurance companies change their minds about ALS patients and Radicava.
If you believe that Mary deserves the same chance,
please sign and share this petition calling on Aetna to provide Radicava to their ALS patients, today.
Be a Seed for Change 
You must be logged in to post a comment.